Australian company Immutep has announced positive efficacy and safety results from the TACTI-003 Phase 2b trial evaluating its eftilagimod alpha in combination with MSD’s KEYTRUDA. …
Immutep says its candidate in combination with Keytruda delivered positive efficacy and safety profile
September 16, 2024 Latest NewsAustralian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 8 May 2026
May 8, 2026 - - Podcast -
Victoria joins state-funded MenB programs as PBAC rejection creates another 'postcode lottery'
May 8, 2026 - - Latest News -
The approaching major change in Australia’s PBS wholesaling arrangements
May 8, 2026 - - Latest News -
Lilly marks 150 years by lighting a new horizon for health at Vivid Sydney
May 8, 2026 - - Latest News -
Stakeholders must act to protect their voice in response to the risk of a manufactured consensus
May 7, 2026 - - Latest News -
Moderna expands support for early career Australian mRNA researchers
May 7, 2026 - - Latest News -
The review is formally over. Why is it restarting?
May 7, 2026 - - Latest News